Share this page

March 11, 2025

EPS Corporation

Notice of Transfer of the Representative Director

EPS Corporation (a CRO and an EPNextS Group company, itself an EPS Holdings Group company, based in Shinjuku, Tokyo, Representative Director: Takehisa Yamada) announces that EPS Corporation's representative director will officially be changed on April 1, 2025 as follows:


New Representative Director Candidate:

Name	New Title	Present Title
Noriyuki Takai	Representative Director and President and Representative Corporate Officer	Board Member and Managing Corporate Officer

Current Representative Director leaving the position:

Name	New Title	Present Title
Takehisa Yamada	Board Member and Chairman and Corporate Officer	Representative Director and President and Representative Corporate Officer

The appointment of the representative director will be resolved at the extraordinary shareholders' meeting and the Board of Directors meeting scheduled for April 1, 2025.


EPS Group's core businesses of CRO, SMO, and CSO are overseen by parent company EPNextS Inc. (EPNextS). This change in the organizational structure is being implemented in accordance with the business policies of EPNextS' medium-term management plan that has been promoted since the current fiscal year.

EPNextS plans to build a new group management structure to boost management capabilities while also improving the front-line capabilities of connected operational companies. The change is part of a series of senior personnel and executive structure changes targeted at fulfilling the EPNextS Group's mid-term goals.

We are working to provide even higher quality services to our clients, strengthen and promote our overseas business, and address Japanese social concerns such as drug lag and drug loss. In addition, we are strengthening our front-line capabilities in areas such as organizational and project management. To grow sustainably in a rapidly changing environment while continuing to provide excellent solutions, we will endeavor to provide new value from a global viewpoint under the new structure as a trusted partner to our clients.


About EPS Corporation
EPS launched its business in 1991 and has grown to be a Top Tier CRO comprehensively supporting clinical trials and post marketing surveillance. The company proposes new models to satisfy customers' needs by leveraging its data science expertise and digital technology, cultivated through its extensive track record. These service offerings are anchored in its Trial GATE concept, which acts as the gateway for clients for access to all clinical trial functions.

About EPNextS, Inc.
EPNextS is a healthcare solutions provider that oversees the EPS Group's core businesses (CRO, SMO, and CSO). These businesses include EPS Corporation, a pioneer in the CRO field since 1991; EP-Link Co., Ltd., which has the largest market share in the SMO field; and EP-PharmaLine Co., Ltd., which provides multiple CSO services, as well as a CRO specializing in foods with health claims development. Bringing together each company's human resources and expertise, the group's approximately 7,000 employees develop novel business solutions in the healthcare industry.